津药药业：子公司津药和平获二氟泼尼酯滴眼液药品注册证书

Core Viewpoint - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has received the drug registration certificate for Difluprednate Eye Drops from the National Medical Products Administration, marking it as the first generic version in China [1] Group 1: Product Development - The drug is primarily used for treating inflammation and pain related to eye surgeries [1] - The total research and development investment for this project has reached approximately 53.27 million yuan [1] Group 2: Market Potential - The projected global sales for Difluprednate Eye Drops are estimated to be 33 million USD in 2023 and 24 million USD in 2024 [1]